FR2829502B1 - NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV) - Google Patents

NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)

Info

Publication number
FR2829502B1
FR2829502B1 FR0210589A FR0210589A FR2829502B1 FR 2829502 B1 FR2829502 B1 FR 2829502B1 FR 0210589 A FR0210589 A FR 0210589A FR 0210589 A FR0210589 A FR 0210589A FR 2829502 B1 FR2829502 B1 FR 2829502B1
Authority
FR
France
Prior art keywords
hiv
analyzing
new method
human immunodeficiency
phenotypic characteristics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0210589A
Other languages
French (fr)
Other versions
FR2829502A1 (en
Inventor
Francois Clavel
Fabrizio Mammano
Esther Race
Elisabeth Dam
Veronique Obry
Virginie Trouplin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103970A external-priority patent/FR2816635A1/en
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Priority to FR0210589A priority Critical patent/FR2829502B1/en
Publication of FR2829502A1 publication Critical patent/FR2829502A1/en
Application granted granted Critical
Publication of FR2829502B1 publication Critical patent/FR2829502B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR0210589A 2001-03-23 2002-08-26 NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV) Expired - Fee Related FR2829502B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0210589A FR2829502B1 (en) 2001-03-23 2002-08-26 NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0103970A FR2816635A1 (en) 2000-11-10 2001-03-23 Analyzing phenotype of human immune deficiency virus, useful for optimizing therapy, by cloning segment into viral particle and transfecting cell containing inducible marker gene
FR0210589A FR2829502B1 (en) 2001-03-23 2002-08-26 NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)

Publications (2)

Publication Number Publication Date
FR2829502A1 FR2829502A1 (en) 2003-03-14
FR2829502B1 true FR2829502B1 (en) 2006-01-13

Family

ID=29404167

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0210589A Expired - Fee Related FR2829502B1 (en) 2001-03-23 2002-08-26 NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)

Country Status (1)

Country Link
FR (1) FR2829502B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6103462A (en) * 1998-05-29 2000-08-15 Institut Pasteur Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance
GB9909793D0 (en) * 1999-04-28 1999-06-23 Glaxo Group Ltd Improved assay and reagents therefor
IL155780A0 (en) * 2000-11-10 2003-12-23 Bioalliance Pharma Novel method for analysing phenotypic characteristics of human imunodeficiency virus (hiv)

Also Published As

Publication number Publication date
FR2829502A1 (en) 2003-03-14

Similar Documents

Publication Publication Date Title
BR0309581A (en) Nucleoside derivatives for treatment of hepatitis c virus infection
DE60208794D1 (en) 4'-SUBSTITUTED NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS C-VIRUS-MEDIATED ILLNESSES
DK0980203T3 (en) Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
DE60235083D1 (en) SUBSTITUTED TETRACYCLIN COMPOUNDS FOR THE TREATMENT OF MALARIA
EA200000840A1 (en) ANTI-VIRUS DERIVATIVES OF PYRIMIDINE
EP1569652A4 (en) N sp 4 /sp-acylcytosine nucleosides for treatment of viral iinfections
DE60219292D1 (en) PYRAZONE DERIVATIVES FOR THE TREATMENT OF HIV
ID26043A (en) 1,2,5-TRIAZINA TRITIZED SUBSTITUTIONS FOR TREATMENT OF HIV INFECTIONS
CA2253490A1 (en) Use of il-12 and ifn-.alpha. for the treatment of infectious diseases
HUP0302636A2 (en) Split enveloped virus preparation
DE60219005D1 (en) SOLID PHARMACEUTICAL FORMULATION CONTAINING MODAFINIL
DE60204466D1 (en) INTEGRINMA TREATMENT FOR THE TREATMENT OF EYE DISEASES
EA200701633A1 (en) VACCINE BASED ON VIRUS-LIKE PARTICLES OF THE HUMAN PAPILLOMA VIRUS 16 AND HUMAN PAPILE VOLUS 18 L1
AU2305202A (en) Novel method for analysing phenotypic characteristics of human immunodeficiency virus (hiv)
AU2002223052A1 (en) Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV)
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
DE50015096D1 (en) THE GENOME OF HIV-1 INTERSUBTYPS (C / B ') AND ITS APPLICATIONS
FR2829504B1 (en) NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)
FR2829502B1 (en) NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)
FR2829501B1 (en) NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
FR2829503B1 (en) NOVEL METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)
ITTO20020284A0 (en) PROCEDURE FOR THE STERILIZATION AND NEUTRALIZATION OF AIR ODOURS.
EP1407042A4 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
RU2000125255A (en) 2 ', 3'-DIDEHYDRO-2', 3'-DIDESOXYTHIMIDIN-5 '[(ETHOXICARBONIL) (Ethyl) PHOSPHONATE] - HUMAN IMMUNODEFICIENCY REPRODUCTION INHIBITOR

Legal Events

Date Code Title Description
TQ Partial transmission of property
CL Concession to grant licenses
ST Notification of lapse

Effective date: 20121130